Tag: Cambridge

Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development Across a Broad Range of Tumors and Advance Pioneering Pipeline and Helicon Platform

Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development Across a Broad Range of Tumors and Advance Pioneering Pipeline and Helicon Platform

Financing co-led by RA Capital Management, Fidelity Management & Research Company, and Janus Henderson Investors CAMBRIDGE, Mass.–(BUSINESS WIRE)–Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer using its…

Read More Read More

MEDIPOST Inc. Announces $140 Million in Funding to Accelerate Late-Stage Clinical Development

MEDIPOST Inc. Announces $140 Million in Funding to Accelerate Late-Stage Clinical Development

Funding will support a planned Phase III U.S. clinical trial in 2026 CAMBRIDGE, Mass.–(BUSINESS WIRE)–MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, today announced that its…

Read More Read More

Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership

Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership

– Startup emerges from Versant’s Frontier Discovery Engine with over $70 million in capital to develop oral macrocyclic peptides – Biogen and Dayra partnership will identify, validate and optimize oral macrocycle candidates for high-priority immunological…

Read More Read More

MindImmune Extends Series A to $30M to Advance Inflammation-Focused Alzheimer’s Therapy into the Clinic and Appoints Isaac Stoner as CEO

MindImmune Extends Series A to $30M to Advance Inflammation-Focused Alzheimer’s Therapy into the Clinic and Appoints Isaac Stoner as CEO

CAMBRIDGE, Mass.–(BUSINESS WIRE)–MindImmune Therapeutics, a private company developing new treatments targeting the inflammatory drivers of neurodegenerative disease, today announced two major milestones: the closing of a $10.2 million Series A extension, which brings the total…

Read More Read More

Addis Energy Secures $8.3M to Scale its Transformative Approach to Low-Cost Ammonia Production

Addis Energy Secures $8.3M to Scale its Transformative Approach to Low-Cost Ammonia Production

The company is producing cost-advantaged ammonia from locations without abundant natural gas supply as it prepares for its first field pilot. CAMBRIDGE, Mass.–(BUSINESS WIRE)–Addis Energy, a company harnessing the Earth’s potential for affordable, abundant ammonia…

Read More Read More

Hemab Therapeutics Announces $157 Million Series C Financing to Advance Next-Generation Treatments for Underserved Bleeding Disorders

Hemab Therapeutics Announces $157 Million Series C Financing to Advance Next-Generation Treatments for Underserved Bleeding Disorders

$157M Series C adds leading life science investors including Sofinnova Partners, a large long-only global asset management company, a large global sovereign wealth fund, and Avoro Capital Advisors Financing readies Hemab for registration studies following successful advancement…

Read More Read More

Pinetree Therapeutics Raises $47 Million in Oversubscribed Series B to Advance Next-Generation Protein Degraders in Oncology

Pinetree Therapeutics Raises $47 Million in Oversubscribed Series B to Advance Next-Generation Protein Degraders in Oncology

CAMBRIDGE, Mass., Oct. 28, 2025 /PRNewswire/ — Pinetree Therapeutics, a preclinical-stage biotechnology company pioneering targeted protein degraders for drug-resistant cancers, announced the successful closing of an oversubscribed $47 million Series B financing. The proceeds will advance its…

Read More Read More

Valink Therapeutics Closes $11.8 Million Pre-A Financing Round to Advance Oncology Pipeline

Valink Therapeutics Closes $11.8 Million Pre-A Financing Round to Advance Oncology Pipeline

Funding accelerates development of novel therapeutics to improve outcomes for patients with cancer CAMBRIDGE, Mass. & LONDON–(BUSINESS WIRE)–Valink Therapeutics Inc. (“Valink”), a private biotechnology company developing next-generation oncology therapeutics with a focus on bispecific antibody-drug…

Read More Read More